Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report

Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Zhang, Yazhou, Zhang, Nu, Ge, Yongsheng, Jia, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752163/
https://www.ncbi.nlm.nih.gov/pubmed/31686845
http://dx.doi.org/10.2147/OTT.S217123
_version_ 1783452745027551232
author Chen, Xin
Zhang, Yazhou
Zhang, Nu
Ge, Yongsheng
Jia, Weidong
author_facet Chen, Xin
Zhang, Yazhou
Zhang, Nu
Ge, Yongsheng
Jia, Weidong
author_sort Chen, Xin
collection PubMed
description Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient’s condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer.
format Online
Article
Text
id pubmed-6752163
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67521632019-11-04 Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report Chen, Xin Zhang, Yazhou Zhang, Nu Ge, Yongsheng Jia, Weidong Onco Targets Ther Case Report Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient’s condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer. Dove 2019-09-09 /pmc/articles/PMC6752163/ /pubmed/31686845 http://dx.doi.org/10.2147/OTT.S217123 Text en © 2019 Chen et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Chen, Xin
Zhang, Yazhou
Zhang, Nu
Ge, Yongsheng
Jia, Weidong
Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
title Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
title_full Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
title_fullStr Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
title_full_unstemmed Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
title_short Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
title_sort lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752163/
https://www.ncbi.nlm.nih.gov/pubmed/31686845
http://dx.doi.org/10.2147/OTT.S217123
work_keys_str_mv AT chenxin lenvatinibcombinednivolumabinjectionfollowedbyextendedrighthepatectomyisafeasibletreatmentforpatientswithmassivehepatocellularcarcinomaacasereport
AT zhangyazhou lenvatinibcombinednivolumabinjectionfollowedbyextendedrighthepatectomyisafeasibletreatmentforpatientswithmassivehepatocellularcarcinomaacasereport
AT zhangnu lenvatinibcombinednivolumabinjectionfollowedbyextendedrighthepatectomyisafeasibletreatmentforpatientswithmassivehepatocellularcarcinomaacasereport
AT geyongsheng lenvatinibcombinednivolumabinjectionfollowedbyextendedrighthepatectomyisafeasibletreatmentforpatientswithmassivehepatocellularcarcinomaacasereport
AT jiaweidong lenvatinibcombinednivolumabinjectionfollowedbyextendedrighthepatectomyisafeasibletreatmentforpatientswithmassivehepatocellularcarcinomaacasereport

Ejemplares similares